Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Aug 23

PMID 34422659

Citations 4

Authors

Blessie Elizabeth Nelson

Angelina Hong

Bagi Jana

Affiliations

Soon will be listed here.

Abstract

Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic chemotherapy regimens have not produced optimal long-term outcomes, and many urothelial cancer patients have comorbidities that disqualify them as chemotherapy candidates. In recent years, a plethora of novel therapeutic agents that target diverse molecular pathways has emerged as alternative treatment modalities for not only metastatic urothelial carcinoma, but also for muscle-invasive bladder cancer and non-muscle invasive bladder cancer in adjuvant and definitive settings. This review paper aims to discuss the various categories of therapeutic agents for these different types of urothelial cancer, discussing immunotherapy, antibody-drug conjugates, kinase inhibitors, CAR-T cell therapy, peptide vaccination, and other drugs targeting pathways such as angiogenesis, DNA synthesis, mTOR/PI3K/AKT, and EGFR/HER-2.

Citing Articles

Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review.

Tang L, Xu H, Wu T, Wu W, Lu Y, Gu J Discov Oncol. 2024; 15(1):111.

PMID: 38602556 PMC: 11009183. DOI: 10.1007/s12672-024-00902-8.

High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes.

Rinaldetti S, Zhou Q, Abbott J, de Jong F, Esquer H, Costello J Int J Mol Sci. 2022; 23(18).

PMID: 36142576 PMC: 9506379. DOI: 10.3390/ijms231810605.

Angioprevention of Urologic Cancers by Plant-Derived Foods.

Garcia-Caballero M, Torres-Vargas J, Marrero A, Martinez-Poveda B, Medina M, Quesada A Pharmaceutics. 2022; 14(2).

PMID: 35213989 PMC: 8875200. DOI: 10.3390/pharmaceutics14020256.

Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology.

Choi H, Naskar M, Seo H, Lee H Biomedicines. 2021; 9(11).

PMID: 34829729 PMC: 8614912. DOI: 10.3390/biomedicines9111500.

References

Lammers R, Witjes W, Janzing-Pastors M, Caris C, Witjes J . Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol. 2012; 30(18):2273-9. DOI: 10.1200/JCO.2011.39.2936. View

Rosenberg J, Sridhar S, Zhang J, Smith D, Ruether D, Flaig T . EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J Clin Oncol. 2020; 38(10):1041-1049. PMC: 7106979. DOI: 10.1200/JCO.19.02044. View

Heath E, Rosenberg J . The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2020; 18(2):93-103. DOI: 10.1038/s41585-020-00394-5. View

Packiam V, Lamm D, Barocas D, Trainer A, Fand B, Davis 3rd R . An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Urol Oncol. 2017; 36(10):440-447. DOI: 10.1016/j.urolonc.2017.07.005. View

Milowsky M, Iyer G, Regazzi A, Al-Ahmadie H, Gerst S, Ostrovnaya I . Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013; 112(4):462-70. PMC: 4020005. DOI: 10.1111/j.1464-410X.2012.11720.x. View

Wang X, Wang H, Song Y . Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients. Oncol Lett. 2019; 17(1):201-208. PMC: 6313094. DOI: 10.3892/ol.2018.9617. View

Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I . A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Ann Oncol. 2016; 28(4):798-803. DOI: 10.1093/annonc/mdw675. View

Bellmunt J, Eigl B, Senkus E, Loriot Y, Twardowski P, Castellano D . Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Ann Oncol. 2017; 28(10):2481-2488. DOI: 10.1093/annonc/mdx400. View

Nishiyama H, Yamamoto Y, Sassa N, Nishimura K, Fujimoto K, Fukasawa S . Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Int J Clin Oncol. 2019; 25(1):165-174. PMC: 6946746. DOI: 10.1007/s10147-019-01545-4. View

10.

Powles T, van der Heijden M, Castellano D, Galsky M, Loriot Y, Petrylak D . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1574-1588. DOI: 10.1016/S1470-2045(20)30541-6. View

11.

Shore N, Boorjian S, Canter D, Ogan K, Karsh L, Downs T . Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017; 35(30):3410-3416. PMC: 5648171. DOI: 10.1200/JCO.2017.72.3064. View

12.

Cao Y, He Y, Chen H, He S, Gu Y, Wang X . Phase I study of gemcitabine-cisplatin versus pemetrexed cisplatin for patients with advanced or metastatic bladder cancer. J BUON. 2018; 23(2):475-481. View

13.

Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S . An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. Clin Cancer Res. 2015; 22(1):54-60. DOI: 10.1158/1078-0432.CCR-15-1265. View

14.

Rosenberg J, Hahn N, Regan M, Werner L, Alva A, George S . Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer. 2018; 118(11):1434-1441. PMC: 5988804. DOI: 10.1038/s41416-018-0087-9. View

15.

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada J . Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer. 2017; 5(1):71. PMC: 5604344. DOI: 10.1186/s40425-017-0277-7. View

16.

Schmid S, Koll F, Rodel C, Maisch P, Sauter A, Beckert F . Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). BMC Cancer. 2020; 20(1):8. PMC: 6942254. DOI: 10.1186/s12885-019-6503-6. View

17.

Prasad N, Muddukrishna S . Quality of transurethral resection of bladder tumor procedure influenced a phase III trial comparing the effect of KLH and mitomycin C. Trials. 2017; 18(1):123. PMC: 5351261. DOI: 10.1186/s13063-017-1843-5. View

18.

Apolo A, Karzai F, Trepel J, Alarcon S, Lee S, Lee M . A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2016; 15(1):77-85. PMC: 6583922. DOI: 10.1016/j.clgc.2016.05.010. View

19.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

20.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View